Five of the World's Top 20 Pharmaceutical Companies Standardize on Veeva Vault eTMF to Manage Clinical Trial Documents Globally

Five of the World's Top 20 Pharmaceutical Companies Standardize on Veeva Vault eTMF to Manage Clinical Trial Documents Globally

More than 50 life sciences organizations move to Veeva Vault eTMF for complete access, visibility, and control of TMF content and processes

PLEASANTON, CA – March 31, 2015 — In the face of increasing clinical trial cost and complexity and changing regulatory guidelines, life sciences companies are turning to cloud-based Veeva Vault eTMF to improve clinical trial master file (TMF) timeliness, completeness, and inspection readiness. In just over a year, five of the world's top 20 pharmaceutical companies have standardized on Veeva Vault eTMF, joining more than 50 Vault eTMF customers – from emerging biotechs to CROs and large pharmas – gaining better access, visibility, and control over clinical trial content and processes.

Regulatory authorities worldwide are placing higher levels of scrutiny on the TMF. The United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) updated its definition of a critical good clinical practice (GCP) finding to include trial master files that are incomplete and inaccessible. There is also a growing recognition of the role TMF management can have in speeding time to market. These changes have prompted an increased focus on actively managing the clinical trial master file throughout the trial process.

Lacking deep, industry-specific capabilities for TMF collaboration, collection, and management, many eTMFs today are simple file shares that serve as document storage. To increase efficiency while strengthening inspection readiness, companies are moving toward process-driven eTMF applications—and seeing major benefits. Those using advanced eTMF technologies report greater audit readiness, visibility, compliance, and cost savings from their eTMF than those using local or cloud file systems.[i]

"A major transformation in TMF management is underway," said Jennifer Goldsmith, vice president of Veeva Vault. "The industry is rapidly moving away from TMFs as simple, static archives. Companies are utilizing TMFs more strategically to improve trial management and long-term trial design and planning, allowing them to bring products to market more quickly and efficiently."

By proactively guiding processes, quality, and visibility at every stage, Vault eTMF is helping companies streamline the clinical development process from start to finish. "Cloud-based solutions for eTMF are becoming the standard for the industry, and Veeva Vault eTMF is leading the charge," said Jamie O'Keefe, vice president of Paragon Solutions' R&D consulting practice. "Before Veeva and cloud, a typical eTMF implementation could take 12 to 18 months and would provide limited capabilities. With Veeva Vault eTMF, implementations take a fraction of the time and organizations are supported by an eTMF application that manages process, enables global collaboration, and ensures inspection readiness."

Veeva Vault eTMF is part of Veeva Vault, a cloud-based content management platform and suite of life sciences-specific applications. Vault eTMF enables real-time collaboration between external partners, internal teams across clinical and regulatory, and study sites globally to deliver a single source of the truth for content. It eliminates the risk and ineffectiveness of manual processes, improving efficiency, visibility, and control. Additionally, Vault eTMF's comprehensive reporting and configurable dashboards provide actionable insights to drive ongoing clinical trial improvement and ensure inspection readiness at all times, in compliance with global health authorities.

About Veeva Vault
Veeva Vault is the first cloud-based regulated content management platform and suite of applications designed for life sciences. It spans clinical, quality, commercial, medical, and every major part of a global life sciences company to ensure one trusted source for content and data across the enterprise. Helping companies connect securely in the life sciences cloud, Vault provides complete control from start to finish, as well as the easy accessibility, visibility, and agility needed to speed time to market. All Vault applications offer real-time reporting and dashboards; an intuitive, consumer-web interface; and a true multitenant cloud architecture that continuously delivers rapid innovation. Today, more than 135 life sciences companies rely upon Vault to manage their most important content.

Additional Information:

• For more information on Veeva Vault, please visit: www.veeva.com/vault/
• Stay updated on the latest Veeva news on LinkedIn: www.linkedin.com/company/veeva-systems
• Follow @veevasystems on Twitter: www.twitter.com/veevasystems
• Like Veeva on Facebook: www.facebook.com/veevasystems

About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 275 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit www.veeva.com.

Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of the Veeva Vault eTMF product, the results from use of the Veeva Vault eTMF product, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates and expectations and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended October 31, 2014, which is available on the company's web site at www.veeva.com under the Investors section and on the SEC's website at www.sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

###

 

Contact:

Lisa Barbadora

Veeva Systems Inc.

610-420-3413

[email protected]

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.